Treatment options in castration-resistant prostate cancer: Current therapies and emerging docetaxel-based regimens

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 2, 2014, Pages 70-79

  Saad, Fred ^a   Miller, Kurt ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Custirsen; Dasatinib; Docetaxel; Prostate cancer; Review; Targeted therapy

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; CLUSTERIN; CUSTIRSEN; DASATINIB; DOCETAXEL; ENZALUTAMIDE; SIPULEUCEL T;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

CUSTIRSEN; DASATINIB; DOCETAXEL; PROSTATE CANCER; REVIEW; TARGETED THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT OUTCOME;

EID: 84892557687     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.01.005     Document Type: Review

References (82)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: IARC, [accessed 2.05.12]. http://globocan.iarc.fr.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Prostate Cancer, V2.2012, [accessed 27.03.12]. http://www.nccn.org.
3. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
4. Marech I., Vacca A., Ranieri G., et al. Novel strategies in the treatment of castration-resistant prostate cancer. Int J Oncol 2012, 40:1313-1320.
5. Maluf F.C., Smaletz O., Herchenhorn D. Castration-resistant prostate cancer: systemic therapy in 2012. Clinics 2012, 67:389-394.
6. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23:8253-8261.
7. Galsky M.D., Vogelzang N.J. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010, 21:2135-2144.
8. Saad F., Hotte S.J. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J 2010, 4:380-384.
9. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003, 21:1232-1237. [Erratum in: J Clin Oncol 2004;22:3434.].
10. Osanto S., Van Poppel H. Emerging novel therapies for advanced prostate cancer. Ther Adv Urol 2012, 4:3-12.
11. TAXOTERE® (docetaxel) [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2010.
12. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010, 10:194-204.
13. Horwich A., Parker C., Bangma C., et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v129-v133.
14. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
15. Tannock I.F., de Wit R., Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 35:1502-1512.
16. Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
17. Berthold D.R., Pond G.R., Roessner M., et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008, 14:2763-2767.
18. PROVENGE® (sipuleucel-T) [package insert]. Seattle, WA: Dendreon Corporation; 2010.
19. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
20. ZYTIGA® (abiraterone acetate) [package insert]. Horsham, PA: Centocor Ortho Biotech, Inc.; 2012.
21. ZYTIGA® approved in the EU for use in the treatment of metastatic castration-resistant prostate cancer before chemotherapy [press release]. Beerse, Belgium: BusinessWire; January 11, 2013. http://www.businesswire.com/news/home/20130111005475/en/ZYTIGA%C2%AE-Approved-EU-Treatment-Metastatic-Castration-Resistant-Prostate.
22. Ryan C.J., Smith M.R., deBono J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148.
23. JEVTANA® (cabazitaxel) [package insert] Bridgewater, NJ: Sanofi-Aventis; 2010.
24. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
25. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
26. JEVTANA® (cabazitaxel) [summary of product characteristics]. Paris, France: Sanofi-Aventis Groupe; 2012.
27. ZYTIGA® (abiraterone acetate) [summary of product characteristics]. Beerse, Belgium: Janssen-Cilag International N.V.; 2012.
28. XTANDI® (enzalutamide) [package insert]. St. Petersburg, FL: Catalent Pharma Solutions, LLC; 2012.
29. Fizazi K., Scher H.I., Molina A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012, 13:983-992.
30. Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197. [Epub ahead of print].
31. FDA approves new treatment for a type of late stage prostate cancer [press release]. Silver Spring, MD. Food and Drug Administration; August 30, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317838.htm.
32. Marín-Aguilera M., Codony-Servat J., Kalko S.G., et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 2012, 11:329-339.
33. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996, 56:1253-1255.
34. Jiang J., Huang H. Targeting the androgen receptor by Taxol in castration resistant prostate cancer. Mol Cell Pharmacol 2010, 2:1-5.
35. Zhu M.L., Horbinski C.M., Garzotto M., et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010, 70:7992-8002.
36. Darshan M.S., Loftus M.S., Thadani-Mulero M., et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011, 71:6019-6029.
37. Gan L., Chen S., Wang Y., et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009, 69:8386-8394.
38. Kuroda K., Liu H., Kim S., et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009, 69:1579-1585.
39. Mezynski J., Pezaro C., Bianchini D., et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. Ann Oncol 2012, [Epub ahead of print].
40. Seruga B., Tannock I.F. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 2011, 29:3686-3694.
41. Seruga B., Ocana A., Tannock I.F. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011, 8:12-23.
42. Dayyani F., Gallick G.E., Logothetis C.J., et al. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011, 103:1665-1675.
43. Arora A., Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005, 315:971-979.
44. Montero J.C., Seoane S., Ocaña A., et al. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011, 17:5546-5552.
45. Park S.I., Zhang J., Phillips K.A., et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008, 68:3323-3333.
46. Nam S., Kim D., Cheng J.Q., et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005, 65:9185-9189.
47. Vandyke K.A.L., Farrugia AN, et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009, 23:994-997.
48. Vandyke K., Dewar A.L., Diamond P., et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res 2010, 25:1759-1770.
49. Id Boufker H., Lagneaux L., Najar M., et al. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 2010, 10:298.
50. Koreckij T., Nguyen H., Brown L.G., et al. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009, 101:263-268.
51. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007, 18:1765-1773.
52. Hodge J.M., Collier F.M., Pavlos N.J., et al. M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One 2011, 6:e21462.
53. Ohno H., Kubo K., Murooka H., et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 2006, 5:2634-2643.
54. Gupta N., Barhanpurkar A.P., Tomar G.B., et al. IL-3 inhibits human osteoclastogenesis and bone resorption through downregulation of c-fms and diverts the cells to dendritic cell lineage. J Immunol 2010, 185:2261-2272.
55. Tanaka S., Takahashi N., Udagawa N., et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993, 91:257-263.
56. Boyce B.F., Yoneda T., Lowe C., et al. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992, 90:1622-1627.
57. Miyazaki T., Sanjay A., Neff L., et al. Src kinase activity is essential for osteoclast function. J Biol Chem 2004, 279:17660-17666.
58. de Vries T.J., Mullender M.G., van Duin M.A., et al. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 2009, 7:476-488.
59. Marzia M., Sims N.A., Voit S., et al. Decrease c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 2000, 51:311-320.
60. Liu Y., Karaca M., Zhang Z., et al. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 2010, 29:3208-3216.
61. Guo Z., Dai B., Jian T., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006, 10:309-319.
62. Mahajan N.P., Liu Y., Majumder S., et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007, 104:8438-8443.
63. ClinicalTrials.gov. NCT01254864. Maximum Androgen Depletion. NCT00988208. Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail). NCT00519285. Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE). NCT00617669. A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer (ENTHUSE M1C). NCT00744497. Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer (READY). NCT01188187. Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY). NCT01083615. A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC). [accessed 23.10.12]. http://clinicaltrials.gov/.
64. Miyake H., Nelson C., Rennie P.S., et al. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000, 60:170-176.
65. Trougakos I.P., So A., Jansen B., et al. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004, 64:1834-1842.
66. Sowery R.D., Hadaschik B.A., So A.I., et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008, 102:389-397.
67. Cetnar J.P., Rosen M.A., Vaughn D.J., et al. Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer. J Clin Oncol 2009, (Suppl.). [abstract e16055]27.
68. Ning Y.M., Gulley J.L., Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:2070-2076.
69. Adamo V., Noto L., Franchina T., et al. Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol 2012, 3:73.
70. Nelson J.B., Fizazi K., Miller K., et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 2012, [Epub ahead of print].
71. Scher H.I., Jia X., Chi K., et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011, 29:2191-2198.
72. Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP® (aflibercept) [press release]. NY: Paris and Tarrytown; April 5, 2012. http://files.shareholder.com/downloads/REGN/0x0x557779/94df2942-a7b5-4ea1-9c17-5ba3bd98c198/REGN_News_2012_4_5_General_Releases.pdf.
73. Celgene announces discontinue phase III MAINSAIL trial; ICON seek first FDA approval of traditional Chinese medicine [press release]. Biomedreports.com; November 22, 2011. http://www.biomedreports.com/2011112384215/celgene-announces-discontinue-phase-iii-mainsail-trial-icon-seeks-first-fda-approval-of-traditional-chinese-medicine.html.
74. Quinn D.I., Tangen C.M., Hussain M., et al. SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J Clin Oncol 2012, Suppl:30. [abstract 4511].
75. S0421 closes early; interim analysis finds no benefit in adding atrasentan to prostate chemotherapy [press release].Swog.org; April 2011. http://swog.org/visitors/newsletters/2011/04/index.asp?a=s0421.
76. Kelly W.K., Halabi S., Carducci M.A., et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010, 28(Suppl.):344s. [abstract LBA4511].
77. Araujo J.C., Mathew P., Armstrong A.J., et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1/2 study. Cancer 2012, 118:63-71.
78. Chi K.N., Hotte S.J., Yu E.Y., et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:4247-4254.
79. Saad F., Hotte S., North S., et al. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 2011, 17:5765-5773.
80. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). Presented at the 2012 American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL. J Clin Oncol 2012; 30 (suppl): [abstract LBA4512].
81. Ortholan C., Durivault J., Hannoun-Levi J.M., et al. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. Eur J Cancer 2010, 46:3022-3036.
82. Banerjee S., Hussain M., Wang Z., et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007, 67:3818-3826.